This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): WX037
Description: WX-037 is an oral small-molecule phosphatidylinositol-3-kinase/proteine-kinase-(PI3K) signalling pathway inhibitor.
In January 2009, UCB Pharma WILEX announced that they agreed to enter into a strategic partnership. WILEX will acquire world-wide rights to develop UCB's entire preclinical oncology portfolio, comprising two small-molecule programmes and three antibody programmes, of which WX-037 is included.
UCB retains exclusive rights to re-purchase each of the five programmes, following completion of initial clinical feasibility studies for each programme, and assume the responsibility for further development and commercialization of each product. In this case, WILEX will receive development and commercialisation milestone payments and royalty payments from UCB.
Alternatively, in the event UCB does not exercise its re-purchase right for each programme, WILEX will retain rights to develop as well as commercialize each programme and UCB will receive milestone and royalty payments from WILEX.
In July 2013, UCB and WILEX announced that UCB got access to an antibody program from...See full deal structure in Biomedtracker
Partners: UCB SA
Additional information available to subscribers only: